From: clinchem.org

" Bladder cancer (BC)1 is the fourth most common cancer and cause of cancer-related deaths in men and the eighth in women; the 5-year survival rate of BC ranges between 30% and 90% (1). The main reasons for the poor survival despite the availability of effective treatment are a high frequency of recurrence (50–80% depending on the initial stage and grade) and lack of a sensitive method for early detection, particularly carcinoma in situ tumors. BC is usually associated with hematuria, dysuria, and frequent urination, but more specific screening tests for BC have not been available until recently.

Several BC tumor markers have been identified recently (2)(3)(4)(5). Among them, bladder tumor antigen (BTA) in urine is a sensitive marker and has been used as an adjunct to cystoscopy in the diagnosis and follow-up of patients with BC (6)(7)(8)(9)(10). BTA statTM and BTA TRAKTM (Alidex) are 2 commercially available assays for BTA in urine. Both assays use 2 monoclonal antibodies (mAbs) that bind to complement factor H (FH)-related material isolated from urine of BC patients (11). The BTA stat is a qualitative cartridge-form enzyme immunoassay, and the BTA TRAK is a quantitative sandwich-type immunoassay in 96-well format. In both assays, the mAb X52.1 is used as the capture antibody and X13.2 as the detection antibody. "

From: karger.co

" The BTA stat is a qualitative test which can be performed in a consultation setting. The BTA TRAK is a quantitative test that is performed in the laboratory. Consecutive patients highly suspicious of bladder cancer were included in this prospective blinded trial to assess the clinical performances of the two methods. Results: A total of 81 patients were tested using BTA stat and BTA TRAK before cystoscopy. A tumor was identified in 49 patients. "